tbuckley/cabot-search huggingface dataset:
Saline alone vs saline plus mannitol hydration for the prevention of acute cisplatin nephrotoxicity: A randomized trial.
Authors: Bradley Beeler, Wilfred P. Delacruz, Frederick L. Flynt, Sandra Terrazzino, Naomi Hullinger, James Aden, Tiffany Byrd, Melissa M. King, Douglas A. Nelson
Journal: Journal of Clinical Oncology (2018)

6035 Background: Cisplatin is a widely used chemotherapeutic in treating malignancies. One of the common side effects of cisplatin is kidney injury, or nephrotoxicity. This can be a reason for discontinuation of treatment. The majority of the cisplatin is excreted by urination. Mannitol is a compound that has been thought to help negate cisplatin -induced nephrotoxicity. Mannitol is a diuretic, causing increased amount of urination, thereby enhancing excretion of cisplatin. Multiple studies have indirectly looked into the effect of mannitol in preventing kidney damage in patients receiving cisplatin. However, there are limited prospective data that evaluate the effect of mannitol in preventing cisplatin-induced nephrotoxicity. In this study, we determine the effects of pre-hydration with mannitol on reducing the risk of cisplatin-induced nephrotoxicity, as opposed to normal saline pre-hydration in patients receiving cisplatin. Methods: 48 patients eligible to receive IV cisplatin therapy at a dose of ≥ 50mg/m2 were identified and randomized to receive 1 L saline alone (A) or saline plus mannitol (B) before and after chemotherapy. Serum creatinine and BUN were drawn on days 1, 5 and 14. Results: Renal function as measured by BUN/Cr ratio, GFR, creatinine, and BUN between group A and B are similar at baseline (BL), day 1, day 5, and day 14. Cisplatin caused acute decline in renal function as determined by ser Cr, BUN to ser Cr ratio and GFR, however, the addition of mannitol to NS pre-hydration did not change the outcome. The decline in renal function is limited to grade 1 and most patients recover Conclusions: Mannitol does not prevent acute nephrotoxicity in patients receiving cisplatin. This underscores the importance of adequate hydration in patients treated with cisplatin. Change in mean values A (n=23) B (n=25) p-value BL to Day 1 Cr -0.047 -0.035 0.647 BUN -0.737 -1.051 0.333 GFR 7.823 7.391 0.462 BL to Day 5 Cr 0.296 -0.0116 0.0801 BUN 11.993 6.229 0.0340 GFR -9.512 -7.073 0.629 BL to Day 14 Cr 0.0606 0.9016 0.833 BUN 1.132 1.641 0.603 GFR -3.772 -2.353 0.594 Grade 1 increase in Cr 25% 17% 0.078
Validity of Reported Genetic Risk Factors for Acute Coronary Syndrome—Reply
Authors: Thomas M. Morgan, Harlan M. Krumholz, Richard P. Lifton, John A. Spertus
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment
Authors: R. E. Weibel
Journal: JAMA (1985)

A clinical trial among 137 healthy children, ages 1 to 12 years, was conducted with four different doses (4,350, 870, 435, and 43 plaque-forming units [pfu]) of live Oka/Merck varicella vaccine to evaluate clinical reactions and selected laboratory parameters and to determine the minimum effective dose and induction time of antibody. The vaccine was well tolerated with no significant difference in the rate of reported symptoms by dose. The frequency of varicellalike rash was 3% (4/137); all rashes were mild. Serum aminotransferase values were essentially unchanged after vaccination. Minor variations found in platelet counts after vaccination were not associated with any bleeding, bruising, or clotting. Among initially seronegative children who received doses of 435 pfu or greater, 94% assayed at two weeks and 100% assayed at four or six weeks seroconverted. The geometric mean titers were similar for all four doses at six weeks. IgG and IgA responses were demonstrated with no relation to the vaccine dose.
Alopecia from oral contraceptives
Authors: F. E. Cormia
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The physician and postmyocardial infarction invalidism
Authors: R. F. Klein
Journal: JAMA (1965)

A study of 20 male survivors of myocardial infarction confirmed a clinical impression that moderate to severe invalidism often occurs in the absence of definable physical residuals of the infarction. The cultural meaning of the heart attack was found to be prominently concerned with fear of sudden death and fear of physical activity. A failure in the revision of concepts derived from the acute phase of the infarction was observed in the invalid patients and their spouses. Physician uncertainty regarding the source of somatic symptoms in invalidism was observed to exert both a delay in the recognition of the syndrome and a perpetuating effect.
Laval Médical, Quebec
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1063: <i>In vivo</i> humanized immuno-oncologymodels for drug discovery
Authors: Jijun Cheng, Feifei Zhang, Yuan Long, Wenhua Xu, Hongkui Chen, Danyi Wen
Journal: Cancer Research (2019)

Abstract Reliable translational, especially humanized mouse models are critical to evaluate efficacy of immuno-therapeutics. While transgenic humanized mice and human CD34+ HSC-reconstituted mice are often used, their human cellular or molecular immune components are limited or defective. Human peripheral blood monocytic cell (PBMC)-reconstitution in immunocompromised mice, although, is transient and limited in infiltrating xenografts, one can manipulate to delicately reconstitute tumor microenvironment with one type, human T cells, or a few types of human immune cells, dendritic and macrophages, from human PBMC, through either systemic reconstitution or local reconstitution. We found that optimized stable PBMC models, both CDX and PDX, can often meet needs of targeting by many developing IO antibody therapeutics, including bi-specifics, in comparison to other humanized models. In particular, for efficacy study and for the convenience of mouse trials, we arrayed panels of PDX models expressing PD-L1 at different levels, in lung, liver, endometrial and gastric cancers, and panels of MSI-H and/or dMMR positive PDX models in these cancer types. In aiding studies of efficacy and resistance, we establish clinically drug-resistant PDX models, such as those resistant to checkpoint antibody drugs. These models are valuable to evaluate efficacy not only for antibody agents but also for combinational therapies involving biotherapeutics such as oncolytic virus. Citation Format: Jijun Cheng, Feifei Zhang, Yuan Long, Wenhua Xu, Hongkui Chen, Danyi Wen. In vivo humanized immuno-oncologymodels for drug discovery [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1063.
JAMA Instructions for Authors
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase II Study of Troxacitabine, a Novel Dioxolane Nucleoside Analog, in Patients With Refractory Leukemia
Authors: Francis J. Giles, Guillermo Garcia-Manero, Jorge E. Cortes, Sharyn D. Baker, Carol B. Miller, Susan M. O'Brien, Deborah A. Thomas, Michael Andreeff, Carol Bivins, Jacques Jolivet, Hagop M. Kantarjian
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To investigate the activity of a novel dioxolane l -nucleoside analog, troxacitabine ( l -(−)-OddC, BCH-4556), in patients with refractory leukemia. PATIENTS AND METHODS: Study participants were patients with refractory or relapsed acute myeloid (AML) or lymphocytic (ALL) leukemia, myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP). Troxacitabine was provided as an intravenous infusion for more than 30 minutes daily for 5 days at a dose of 8.0 mg/m 2 /d (40 mg/m 2 per course). Courses were given every 3 to 4 weeks according to antileukemic efficacy. RESULTS: Forty-two patients (AML, 18 patients; MDS, one patient; ALL, six patients; CML-BP, 17 patients) were treated. Median age was 51 years (range, 23 to 80 years); 22 patients were male. Stomatitis was the most significant adverse event, with three patients (7%) and two patients (5%), respectively, experiencing grade 3 or 4 toxicity. Ten patients (24%) had grade 3 hand-foot syndrome, and two patients (5%) had grade 3 skin rash. One patient (2%) had grade 3 fatigue and anorexia. Marrow hypoplasia occurred between days 14 and 28 in 12 (75%) of 16 assessable patients with AML. Two complete remissions and one partial remission (18%) were observed in 16 assessable patients with AML. None of six patients with ALL responded. Six (37%) of 16 assessable patients with CML-BP experienced a return to chronic-phase disease. CONCLUSION: Troxacitabine has significant antileukemic activity in patients with AML and CML-BP.
Observations ON THE PATHOLOGY OF CARDIAC DROPSY: Being the Oliver-Sharpey Lectures delivered before the Royal College of Physicians of London, May, 1917
Authors: C. Bolton
Journal: BMJ (1917)

34-4 2 Totals ... 1,371 £362 1 5 Total number of splints made from October 28th to March 10th, 1,371.Cash value at pre-war prices, £362 is.5d.Of the above 4eturns 1,013 are stock pattern splints, namely, cock-up splints, gutters, club-foot shoes, crab (long and short), Turner's arm, whole hand-splints.The balance (358) are special splints designed in workshops, and made to surgeolns' instructions.Quantity of Orthopaedic Repairs by thte Bootmaker.The total number of cases requiring orthopaedic repairs by the bootmaker from October 21st, 1916, to March 4th, 1917, was 361.This was apart from ordinary repairs.The work conisisted of inside and outside elevations, T-straps, cork soles, bars on soles, crooked heels, surgical boots and alterations according to medical orders.Painting, Drawing, Photographic Department.This department is under the control of Mr. Bird, the distinguislhed artist, wlho is assisted in photograplhy by Mr. Lewis.Here not only photographs and drawings of cases during the various stages of treatmeiit and splints used are made, but actual paintings in natural colour whenever the surgeon thinks it necessary.In this way can be kept complete records of operation cases, which are especially valuable in demonstration for teaching purposes.X Rays.This department is fully equipped with all the latest methods for x-ray photography,under tlle supervision of Captain Keys-Wells, R.A.M.C., who attends the hospital daily
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
But, Doctor
Authors: Nishtha Sodhi
Journal: Annals of Internal Medicine (2013)

Ad Libitum15 January 2013But, DoctorNishtha Sodhi, MDNishtha Sodhi, MDFrom Cleveland Clinic, Cleveland, Ohio.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-2-201301150-00012 Audio Reading - “But, Doctor” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "But, Doctor," by N. Sodhi Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail But, Doctor, we're supposed to go down the shore next weekendShe bought orange flip-flops with floppy blue flowersAnd a yellow summer dress to sashay her skinny bones inShe thinks she's a real fashionista, you knowShe even bought an oversized beach towel that we're gonna share to soak up that sunYou already have such nice color to your skin, DoctorBut my baby, she's always so paleDo they have cotton candy ... Author, Article, and Disclosure InformationAffiliations: From Cleveland Clinic, Cleveland, Ohio.Current Author Address: Nishtha Sodhi, MD, Cleveland Clinic, PGY 2, Department of Internal Medicine, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail, [email protected]. PreviousarticleNextarticle Advertisement Audio Reading - “But, Doctor” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads "But, Doctor," by N. Sodhi Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 15 January 2013Volume 158, Issue 2Page: 136KeywordsBoneGraduate medical educationSmell ePublished: 15 January 2013 Issue Published: 15 January 2013 CopyrightCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Grinding the Cornea
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply: Internal Malignancy in Genetic Hemochromatosis
Authors: Robin A. Bradbear, M.D.
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Reply: Internal Malignancy in Genetic Hemochromatosis Get access Robin A. Bradbear, M.D. Robin A. Bradbear, M.D. Department of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, 4029 Australia Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 76, Issue 6, June 1986, Page 1261, https://doi.org/10.1093/jnci/76.6.1261 Published: 01 June 1986
In Reply
Authors: Maren Weischer, Stig E. Bojesen, Børge G. Nordestgaard
Journal: Journal of Clinical Oncology (2008)

We read with interest the article by Weisher et al 1 in which the authors recommend genotyping for CHEK2*1100delC, in addition to BRCA1 and BRCA2 mutation screening, for women with a family history of breast cancer.In their report, only Northern or Eastern European ethnic groups and not other ethnic groups, were subjected to meta-analyses to determine breast cancer risks associated with this CHEK2 mutation. 13][4][5][6] Table 1 presents a summary of the Asian subjects that have been screened for the CHEK2*1100delC mutation.None of our 94 Singaporean subjects of Asian descent who underwent genetic testing for BRCA1 and BRCA2 mutations utilizing a comprehensive strategy had the CHEK2*1100delC mutation.Screening was done using the multiplex ligation-dependent probe amplification method (P045 BRCA2/CHEK2 kit; MRC-Holland, Amsterdam, the Netherlands). 5All of these women had either a family history of breast or ovarian cancer or early-onset breast cancer, and were predominantly of Chinese, Malay, and Indian ethnicities. 5erefore, based on the reasons outlined above and the points mentioned by Offit and Garber 7 pertaining to population heterogeneity, cancer spectrum, variable penetrance, and the occurrence of phenocopies, we believe that genetic testing for CHEK2*1100delC in Asian women with a family history of breast cancer is not warranted.
代谢综合征和银屑病的风险
Authors: I. Snekvik, T.I.L. Nilsen, P.R. Romundstad, M. Saunes
Journal: British Journal of Dermatology (2019)

银屑病是一种常见的慢性皮肤病,与代谢综合征相关,但很少有人研究哪一个先出现 - 是银屑病还是代谢综合征。代谢综合征指腹部肥胖、不良水平的血脂、血压升高和胰岛素抵抗,且与心血管疾病的风险显著增高相关。此研究的研究者来自挪威,他们在 11 年中随访了 35 000 名男性和女性。他们旨在明确患有代谢综合征是否会增加患银屑病的风险。在此研究开始时,对所有参与者进行了临床检查,在其中测量了身高、体重、腰围和血压。采集了血样,参与者们回答了一份问卷。在此期间,374 人发生了银屑病。研究者们发现,与无代谢综合征的人相比,代谢综合征患者首次发生银屑病的风险增高 66%。在研究代谢综合征的不同成分时,他们发现腹部肥胖是此关联中最重要的因素。这项研究显示,正常体重和避免成组的心血管风险因素可能有助于预防银屑病。
Cardiovascular Disease
Authors: Joel M. Gore
Journal: JAMA (1995)

The most common cardiovascular causes of hospital admission in the United States are unstable angina and non—Q-wave myocardial infarction. The efficacy of thrombolytic therapy in patients with these disorders is unclear, and the role of routine early coronary arteriography followed by revascularization is uncertain. The Thrombolysis in Myocardial Ischemia trial randomized 1473 patients with unstable angina or non—Q-wave myocardial infarction in a 2×2 factorial design comparing (1) tissue-type plasminogen activator vs placebo and (2) an early invasive strategy vs an early conservative strategy.<sup>1</sup>The investigators found that thrombolytic therapy was not beneficial and may be harmful. With respect to early coronary arteriography, there was no difference in mortality or recurrent myocardial infarction at 6 weeks. There was, however, a reduction in days of hospitalization and rehospitalization and in the use of antianginal drugs. The current approach to the treatment of patients with acute coronary syndromes is to administer intravenous